Owned and operated by a cf veteran 
Updated August 2026: Retatrutide is an investigational triple-hormone receptor agonist being studied for obesity, type 2 diabetes and related cardiometabolic conditions. It is not an approved consumer medication, and its complete safety profile is still being established.
Current clinical evidence shows a consistent pattern: gastrointestinal side effects are the most common, usually occur during dose escalation and are generally mild to moderate. Higher studied doses have tended to produce more adverse events and more treatment discontinuations. Less common findings—including changes in heart rate, altered skin sensation and isolated pancreatic or gallbladder events—also deserve careful attention.
This guide reviews what the peer-reviewed Phase 2 trial and the latest 2026 Phase 3 topline results actually report. It is educational research commentary, not medical advice or a recommendation to use retatrutide.
Retatrutide side effects at a glance
| Finding | What clinical trials reported |
|---|---|
| Diarrhea | One of the most frequent events; reported by 27.4%–33.6% of retatrutide groups in TRIUMPH-2 versus 13.2% with placebo. |
| Nausea | Reported by 13.7%–28.0% in TRIUMPH-2 versus 8.0% with placebo. |
| Constipation | Reported by 14.0%–16.8% in TRIUMPH-2 versus 9.4% with placebo. |
| Vomiting | Reported by 5.5%–15.7% in TRIUMPH-2 versus 4.2% with placebo. |
| Decreased appetite | Reported by 5.8%–17.1% in TRIUMPH-2 versus 4.5% with placebo. |
| Altered skin sensation | Dysesthesia occurred in 4.5%–7.3% of TRIUMPH-2 groups versus 0.7% with placebo. |
| Treatment discontinuation | In TRIUMPH-2, 3.8%–11.6% discontinued because of adverse events, compared with 4.9% on placebo. |
The Phase 3 figures above come from the trial sponsor’s July 2026 topline announcement. Detailed TRIUMPH-2 and TRIUMPH-3 results had not yet been published in a peer-reviewed journal when this article was updated.
Why retatrutide affects the digestive system
Retatrutide activates three receptors: glucose-dependent insulinotropic polypeptide (GIP), glucagon-like peptide-1 (GLP-1) and glucagon. This “triple agonist” design distinguishes it from single- and dual-receptor compounds. Its GLP-1 activity can influence appetite and gastrointestinal function, which helps explain why nausea, diarrhea, vomiting and constipation repeatedly appear in trial data.
In the peer-reviewed Phase 2 obesity trial, gastrointestinal events occurred mainly while doses were being increased. They were predominantly mild to moderate, more frequent in higher-dose groups and partly reduced when participants began at the lower studied starting dose. Read our separate explanation of retatrutide’s effects on digestion for more detail.
What the Phase 2 safety data found
The pivotal Phase 2 obesity study enrolled 338 adults and followed participants for 48 weeks. Across the retatrutide groups, 73%–94% reported at least one adverse event, compared with 70% in the placebo group. Adverse events led to discontinuation in 6%–16% of retatrutide participants and none of the placebo participants.
Serious adverse events occurred in 4% of the combined retatrutide group and 4% of the placebo group. That similar percentage is reassuring only in a limited sense: the trial was not large or long enough to rule out uncommon or delayed risks.
The investigators also reported:
- A dose-dependent increase in heart rate that peaked around week 24 and declined afterward.
- Skin sensitivity or cutaneous hyperesthesia in 7% of retatrutide participants versus 1% with placebo.
- One serious case of acute pancreatitis.
- Three gallbladder-related events: one case of cholecystitis and two cases of cholelithiasis.
- Transient liver-enzyme elevations above three times the upper limit of normal in 1% of retatrutide participants.
- No clinically significant hypoglycemia, medullary thyroid cancer or C-cell hyperplasia during the trial.
“No cases observed” is not the same as “no risk.” Rare outcomes may emerge only after larger studies or longer follow-up.
What changed with the 2026 Phase 3 results?
In July 2026, the trial sponsor released topline safety and efficacy findings from TRIUMPH-2 and TRIUMPH-3. Together, the trials included more than 3,000 participants and ran for 80 weeks.
The most common events remained gastrointestinal. In TRIUMPH-2, diarrhea affected 27.4%–33.6% of retatrutide groups, nausea 13.7%–28.0%, constipation 14.0%–16.8%, and vomiting 5.5%–15.7%. TRIUMPH-3 produced a similar overall pattern.
Most of these events were described as mild to moderate, and the majority resolved during treatment. However, adverse-event discontinuation reached 13.5% in the 12 mg TRIUMPH-3 group versus 4.8% with placebo. This reinforces the Phase 2 observation that tolerability can vary by dose and population.
Are there serious retatrutide risks?
Retatrutide remains investigational, so there is no final regulator-approved product monograph defining every contraindication, interaction and warning. The safety signals being watched include:
Persistent gastrointestinal symptoms and dehydration
Repeated vomiting or diarrhea can lead to dehydration and electrolyte disturbance. Severe, persistent or worsening symptoms require professional medical assessment.
Pancreatic and gallbladder events
The Phase 2 trial recorded one serious acute pancreatitis event and several gallbladder events. These numbers are too small to establish a precise risk rate, but they remain clinically important observations.
Heart-rate changes
Retatrutide produced dose-dependent increases in heart rate in Phase 2. Researchers are continuing to assess the longer-term cardiovascular significance. Anyone experiencing chest pain, fainting, a sustained rapid heartbeat or severe shortness of breath should seek urgent care.
Altered skin sensation
Hyperesthesia and dysesthesia describe unusual sensitivity, tingling, burning or discomfort without an obvious skin injury. These events were generally not severe in trials, but they appeared more often with retatrutide than placebo.
Unknown long-term effects
Phase 3 studies greatly expand the evidence base, but they cannot immediately answer questions about multi-year exposure, rare events or use in populations that were excluded from trials.
Does retatrutide cause fatigue?
Fatigue is widely discussed online, but the best interpretation depends on context. Reduced food intake, gastrointestinal symptoms, dehydration, sleep disruption and changes in glucose can all contribute to tiredness. Our focused guide, Does Retatrutide Make You Tired?, separates trial findings from online anecdotes.
Retatrutide safety compared with Ozempic and Mounjaro
Retatrutide, semaglutide and tirzepatide do not activate the same combination of receptors, and they should not be treated as interchangeable. Gastrointestinal side effects occur across this broader drug class, but direct head-to-head evidence is limited. Retatrutide’s investigational status also means there is less post-market safety information than exists for approved medicines.
See our evidence-based Retatrutide vs Ozempic comparison for the key mechanism, evidence and regulatory differences.
Frequently asked questions
What is the most common side effect of retatrutide?
Gastrointestinal symptoms are the most common category. Diarrhea, nausea, constipation and vomiting appeared most frequently in the 2026 Phase 3 topline data.
Do retatrutide side effects get worse at higher doses?
Phase 2 results showed more gastrointestinal adverse events in higher-dose groups, and a lower studied starting dose partially improved tolerability. This is a trial observation, not a dosing recommendation.
How long do retatrutide side effects last?
Trials reported that many gastrointestinal events occurred during dose escalation and were temporary, but published data do not provide one duration that applies to every person or symptom.
Does retatrutide cause cancer?
No medullary thyroid cancers or C-cell hyperplasia were reported in the 48-week Phase 2 obesity trial. That finding does not prove the absence of long-term or rare risk. Larger studies and regulatory review are needed.
Is retatrutide approved in Canada?
Retatrutide remains an investigational compound. The trial sponsor stated in July 2026 that it planned to seek U.S. approval in 2027. It should not be represented as an approved therapeutic product.
Bottom line
Available evidence consistently identifies gastrointestinal symptoms as the most common retatrutide side effects. Most were mild to moderate and often occurred during dose escalation, but treatment discontinuation, heart-rate changes, altered skin sensation and uncommon serious events show why the compound still requires rigorous clinical evaluation.
Online anecdotes cannot establish safety. The strongest information comes from controlled trials, and the 2026 Phase 3 findings remain topline results until full peer-reviewed reports are available.
Research-use notice: This article is for educational and research-reference purposes only. It does not provide medical advice, diagnosis, treatment instructions or a recommendation for human or animal use. Red Leaf Research Labs products are sold for research use only.
Sources
- Jastreboff AM et al. Triple–Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial. New England Journal of Medicine (2023).
- Rosenstock J et al. Retatrutide in people with type 2 diabetes: Phase 2 trial. The Lancet (2023).
- TRIUMPH-2 and TRIUMPH-3 sponsor-reported topline results (July 23, 2026).
